Solitary fibrous tumor is a rare spindle cell mesenchymal tumor entity, with either benign or malignant behavior that cannot be accurately predicted by histological findings. An intrapulmonary site of origin is even rarer. We report a case of a 51-year-old woman in whom an abnormal nodule in the lower right lung was detected during staging for sigmoid adenocarcinoma. The nodule was excised and pathological examination revealed an intrapulmonary solitary fibrous tumor.
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CASE REPORT
A 51-year-old Caucasian female was referred to our institution because of an abnormal nodule detected in her right lung. This had at first been detected four months earlier when she underwent an urgent Hartmann procedure due to refractory adenocarcinoma of the sigmoid colon (pT4N1 stage).
Due to the urgency of the surgery, the patient was not staged prior to the surgery but was initially staged after the operation. The only pathologic finding in the computed tomography (CT) of the lung was a nodule in the lower right lobe of 2.5 cm at its longest dimension ( Fig. 1) , and the patient was staged as cT4N1M1. She received 4 cycles of chemotherapy for the sigmoid adenocarcinoma before she was SFTs of the pleura and lung occur predominantly in adults.
Nevertheless, there are rare cases of intrapulmonary SFTs reported in childhood [6] . They are usually found incidentally.
Possible symptoms include cough, pain and dyspnea, and dig-
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− 297 − On gross examination, the tumor is generally well-circum- Resection with free margins is considered to be the treatment for SFT located either in the lung or on the pleura. Wedge resection may be accomplished by VATS or standard thoracotomy, according to the anatomic position and size of the lesion and the experience of the surgeon [2, 4] . Adjuvant therapy may have a place in recurrent or systemic disease, but its benefit is undefined [5] . In general, SFTs have an unpredictable course, depending on their potential for malignancy. In large series, the recurrence rate of benign SFTs is reported to be low (1.4%), while the recurrence rate of malignant variants is reported to be higher (range, 9% to 19%) [1, 5] .
A staging system based on pedunculated versus sessile attachment and malignant versus benign histology that predicts recurrence has been proposed by Perrot et al. [1] (Table 1) .
Due to the possibility of local recurrence and/or distal metastasis after surgical removal of the primary SFT, long-term follow-up is recommended. Local recurrence detected early is amenable to reoperation and resection, with good long-term results. The long-term survival rate for both benign and malignant variants is reported to be more than 90% [1] [2] [3] 6 ].
In conclusion, SFTs are neoplasms that usually arise from 
